Pharnext S.A.. (2/7/17). "Press Release: Pharnext to Present at 2017 BIO CEO & Investor Conference". Paris.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Pharnext S.A. (Euronext Paris: ALPHA)
	Organisation 2	BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization)
	Product	BIO CEO & Investor Conference 2017 New York
	Product 2	PXT-3003 (Pharnext)
	Index term	Pharnext–BIO (US): investor conference, 201702 supply service Pharnext SA presents at BIO CEO & Investor Conference NY
	Index term 2	Pharnext–Stern IR: public relations, 201701 service existent US Investor Relations by Stern IR
	Person	McCabe, Sarah (Stern Investor Relations 201701)

Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.

The presentation will take place as follows:
> Date: Monday, February 13th, 2017
> Time: 10:00 am ET (4:00 pm CET)
> Venue: The Waldorf Astoria in New York, New York.

If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at sarah@sternir.com

About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

Record changed: 2023-06-05